The lncRNA MIR2052HG was reported to increase ERα expression, leading to augmented cell proliferation in ERα+ BC cells and consequently reducing the response to AIs in adjuvant therapy for early-stage BC. This evidence concerns the gene ESR1 and breast cancer.